• Publications
  • Influence
Rat models of hypertension, cardiac hypertrophy and failure.
TLDR
There is often insufficient consideration as to whether the other criteria, especially the mimicry of human disease, are satisfied with the choice of rat models of cardiovascular disease, and three examples illustrate the problems. Expand
Adherence to Medicines in the Older-Aged with Chronic Conditions
TLDR
There are many unanswered questions about the most effective interventions for promoting adherence and more studies are needed to determine the most appropriate interventions by allied health professionals, and such studies need to consider the disease state, demographics and socioeconomic status of the older-aged subject, and the intensity and duration of intervention. Expand
Comparison of clinical trials with sildenafil, vardenafil and tadalafil in erectile dysfunction
  • S. Doggrell
  • Medicine
  • Expert opinion on pharmacotherapy
  • 1 January 2005
TLDR
Of the phosphodiesterase inhibitors, tadalafil may displace sild-enafil as the drug of choice among men with ED, possibly because of its longer duration of action. Expand
Vascular chymase: pathophysiological role and therapeutic potential of inhibition.
TLDR
Oral active inhibitors of chymase may have a place in the treatment of vascular diseases where injury-induced mast cell degranulation contributes to the pathology, and results have been obtained in animal models of atherosclerosis and angiogenesis. Expand
Sarpogrelate: cardiovascular and renal clinical potential
  • S. Doggrell
  • Medicine
  • Expert opinion on investigational drugs
  • 1 July 2004
TLDR
Small clinical trials indicate that sarpogrelate may be beneficial in the treatment of coronary artery disease, angina, restenosis, heart valve prostheses surgery, diabetes mellitus, Raynaud's phenomenon, systemic sclerosis and Buerger’s disease. Expand
Relaxant and β2‐adrenoceptor blocking activities of (±)‐, (+)‐and (—)‐pindolol on the rat isolated aorta
  • S. Doggrell
  • Chemistry, Medicine
  • The Journal of pharmacy and pharmacology
  • 1 June 1990
TLDR
At 10−7 M ICI 118,551, (±)‐, (+)‐and (‐)‐pindolol were β2‐adrenoceptor antagonists as they inhibited the relaxant responses of the aorta to procaterol. Expand
Fondaparinux versus enoxaparin for the prevention of venous thromboembolism
  • S. Doggrell
  • Medicine
  • Expert opinion on pharmacotherapy
  • 1 April 2002
TLDR
In patients undergoing hip-fracture surgery, fondaparinux is more effective than once-daily enoxaparin as prophylaxis for venous thromboembolism. Expand
Berberine – a novel approach to cholesterol lowering
  • S. Doggrell
  • Medicine
  • Expert opinion on investigational drugs
  • 1 May 2005
TLDR
Berberine upregulates the LDL receptor (LDLR) by a mechanism distinct from that of the statins, which involves stabilising the LDLR mRNA, and the other effects of berberine (antihypertensive, inotropic and class III antiarrhythmic properties) may make it a useful agent in the treatment of cardiovascular disease. Expand
The role of 5-HT on the cardiovascular and renal systems and the clinical potential of 5-HT modulation
  • S. Doggrell
  • Medicine
  • Expert opinion on investigational drugs
  • 1 May 2003
TLDR
The main peripheral sources of 5-hydroxytryptamine (5-HT) are as a neurotransmitter and local hormone in the gastrointestinal tract, and stored in circulating platelets and pulmonary neuroepithelial bodies, and in diabetes, sarpogrelate may protect against nephropathy. Expand
BMS-354825: a novel drug with potential for the treatment of imatinib-resistant chronic myeloid leukaemia
  • S. Doggrell
  • Medicine
  • Expert opinion on investigational drugs
  • 1 January 2005
TLDR
BMS-354825 treatment of immunodeficient mice prevented the progression of the disease in mice treated with the most clinical common imatinib-resistant mutant Met351Thr and the frequency of clinical use in CML patients will depend on its efficacy/safety profile in clinical trial. Expand
...
1
2
3
4
5
...